fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article 'Risk stratification in the older patient: what are our priorities?'

Written by | 31 May 2016

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Written by | 25 Jan 2016

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.